What's Happening?
Sonire Therapeutics, a clinical-stage medical device company, has raised $18 million in a Series A financing round led by Santé Ventures, with participation from Fast Track Initiative, Nomura SPARX Investment, and SBI Investment. The funds will support
the development of Sonire's proprietary High-Intensity Focused Ultrasound (HIFU) therapy system, designed for the non-invasive thermal ablation of solid tumors, particularly targeting pancreatic cancer. This technology offers several advantages over conventional methods, including enhanced real-time visualization, outpatient convenience, and reduced staffing requirements. The device has received an FDA Breakthrough Device Designation and aims to improve survival rates when combined with chemotherapy.
Why It's Important?
Pancreatic cancer is a highly lethal disease with limited treatment options and a low five-year survival rate of 12%. Sonire's HIFU system represents a significant advancement in providing a safer and more efficient alternative to traditional surgery or radiation. By reducing the need for anesthesia and allowing outpatient procedures, the technology could lower healthcare costs and improve patient accessibility. The successful development and implementation of this system could set a new standard of care, potentially extending the lives and improving the quality of life for patients with pancreatic cancer.
What's Next?
The funding will facilitate the completion of the SUNRISE-I randomized controlled trial in Japan, which is the first study to evaluate HIFU combined with chemotherapy for pancreatic cancer. Sonire is also expanding its operations to Palo Alto, California, as it prepares for U.S. clinical and regulatory milestones. The company aims to demonstrate that its next-generation acoustic engineering can address the challenges of precision and workflow in oncology, potentially leading to broader adoption of its technology in the U.S. and globally.
